Doxorubicin Hydrochloride Liposome is a Intravenous Injection, Suspension, Liposomal in the Human Prescription Drug category. It is labeled and distributed by Baxter Healthcare Corporation. The primary component is Doxorubicin Hydrochloride.
Product ID | 0338-0086_1bbcb035-47b4-4a83-abf6-74c33725d3ec |
NDC | 0338-0086 |
Product Type | Human Prescription Drug |
Proprietary Name | Doxorubicin Hydrochloride Liposome |
Generic Name | Doxorubicin Hydrochloride Liposome |
Dosage Form | Injection, Suspension, Liposomal |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2019-08-15 |
Marketing Category | NDA / NDA |
Application Number | NDA050718 |
Labeler Name | Baxter Healthcare Corporation |
Substance Name | DOXORUBICIN HYDROCHLORIDE |
Active Ingredient Strength | 2 mg/mL |
Pharm Classes | Anthracycline Topoisomerase Inhibitor [EPC],Anthracyclines [CS],Topoisomerase Inhibitors [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2021-12-31 |